Medtronic has announced the launch of the Avalus Ultra valve, an advanced surgical aortic tissue valve.
The valve is engineered to simplify the implantation process and facilitate lifetime patient management.
The Avalus Ultra surgical valve features a low valve profile to ease implantation and a polyetheretherketone (PEEK) base frame for consistent circularity.
It boasts an industry-leading Effective Orifice Area (EOA) for improved blood flow, supported by the clinical evidence of the Avalus valve.
The new valve builds upon a decade of clinical experience and the proven durability of Medtronic’s Avalus valve.
Medtronic Cardiovascular portfolio cardiac surgery, structural heart, and mechanical circulatory support businesses vice-president and chief medical officer Pieter Kappetein said: “Patients with aortic stenosis are experiencing more complex disease, and therefore, procedures need to evolve to optimize their surgical care.
“Rooted in this evolving need, surgeons are demanding innovative technologies like the Avalus Ultra valve that is designed for increased ease of use and long-term durability to serve patients over their lifetime.”
Additionally, a radiopaque coil of the valve ensures clear visibility for future valve-in-valve procedures.
Medtronic cardiac surgery business president Karim Bandali said: “Cardiac surgeons are looking to industry to partner with them to deliver improved innovation to treat their patients efficiently and effectively.
“The Avalus Ultra valve builds on several successful innovation launches this year, including the acquisition and launch of the Penditure LAA Exclusion System. Aligned with our mission, Medtronic is committed to making the investments needed to advance and deliver innovative, lifesaving devices for better lifetime patient management.”
Approved by the US Food and Drug Administration as of January 2024, the Avalus Ultra valve is currently available exclusively in the US.
Last month, Medtronic introduced live streaming to its Touch Surgery Ecosystem (TSE).
